AU2001264736B2 - Gabapentin analogues for sleep disorders - Google Patents

Gabapentin analogues for sleep disorders Download PDF

Info

Publication number
AU2001264736B2
AU2001264736B2 AU2001264736A AU2001264736A AU2001264736B2 AU 2001264736 B2 AU2001264736 B2 AU 2001264736B2 AU 2001264736 A AU2001264736 A AU 2001264736A AU 2001264736 A AU2001264736 A AU 2001264736A AU 2001264736 B2 AU2001264736 B2 AU 2001264736B2
Authority
AU
Australia
Prior art keywords
acetic acid
aminomethyl
cyclopentyl
cyclobutyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001264736A
Other languages
English (en)
Other versions
AU2001264736A1 (en
Inventor
Justin Stephen Bryans
Leonard Theodore Meltzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU2001264736A1 publication Critical patent/AU2001264736A1/en
Application granted granted Critical
Publication of AU2001264736B2 publication Critical patent/AU2001264736B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001264736A 2000-06-26 2001-05-18 Gabapentin analogues for sleep disorders Ceased AU2001264736B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21417100P 2000-06-26 2000-06-26
US60/214,171 2000-06-26
PCT/US2001/016343 WO2002000209A2 (en) 2000-06-26 2001-05-18 Gabapentin analogues for sleep disorders

Publications (2)

Publication Number Publication Date
AU2001264736A1 AU2001264736A1 (en) 2002-03-28
AU2001264736B2 true AU2001264736B2 (en) 2006-04-27

Family

ID=22798045

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001264736A Ceased AU2001264736B2 (en) 2000-06-26 2001-05-18 Gabapentin analogues for sleep disorders
AU6473601A Pending AU6473601A (en) 2000-06-26 2001-05-18 Gabapentin analogues for sleep disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU6473601A Pending AU6473601A (en) 2000-06-26 2001-05-18 Gabapentin analogues for sleep disorders

Country Status (23)

Country Link
US (1) US7141606B2 (enExample)
EP (1) EP1296671B1 (enExample)
JP (1) JP3909842B2 (enExample)
KR (1) KR100785182B1 (enExample)
CN (1) CN1279900C (enExample)
AT (1) ATE390133T1 (enExample)
AU (2) AU2001264736B2 (enExample)
BR (1) BR0111913A (enExample)
CA (1) CA2414008C (enExample)
CZ (1) CZ20024110A3 (enExample)
DE (1) DE60133389T2 (enExample)
DK (1) DK1296671T3 (enExample)
ES (1) ES2300332T3 (enExample)
HU (1) HUP0300833A3 (enExample)
IL (2) IL152770A0 (enExample)
MX (1) MXPA02010668A (enExample)
NZ (1) NZ522480A (enExample)
PL (1) PL359872A1 (enExample)
PT (1) PT1296671E (enExample)
SK (1) SK17922002A3 (enExample)
TW (1) TWI298020B (enExample)
WO (1) WO2002000209A2 (enExample)
ZA (1) ZA200209418B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085839A1 (en) 2001-04-19 2002-10-31 Warner-Lambert Company Llc Fused bicyclic or tricyclic amino acids
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7420002B2 (en) 2001-06-11 2008-09-02 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
MXPA03011566A (es) 2001-06-11 2004-10-28 Xenoport Inc Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida.
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
US7026351B2 (en) 2002-03-20 2006-04-11 Xenoport, Inc. Cyclic 1-(acyloxy)-alkyl prodrugs of GABA analogs, compositions and uses thereof
AU2003243180A1 (en) 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7060727B2 (en) 2002-12-11 2006-06-13 Xenoport, Inc. Prodrugs of fused GABA analogs, pharmaceutical compositions and uses thereof
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
AU2003283718A1 (en) * 2002-12-13 2004-07-09 Warner-Lambert Company Llc Gabapentin analogues for fibromyalgia and other related disorders
WO2004093827A2 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Phenolic acid salts of gabapentin in solid dosage forms and methods of use
KR20060119971A (ko) 2003-09-11 2006-11-24 제노포트 인코포레이티드 Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
WO2005027850A2 (en) 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
MXPA06004088A (es) 2003-10-14 2006-06-27 Xenoport Inc Forma cristalina de un analogo del acido gamma-aminobutirico.
JP4613031B2 (ja) * 2004-05-06 2011-01-12 エスエス製薬株式会社 催眠剤組成物
JP2005325070A (ja) * 2004-05-14 2005-11-24 Ss Pharmaceut Co Ltd 睡眠改善剤
EP1811986B1 (en) 2004-11-04 2014-03-26 XenoPort, Inc. Gabapentin prodrug sustained release oral dosage forms
JP2009505947A (ja) 2005-06-23 2009-02-12 エモリー・ユニバーシティ 画像化剤
KR20070070307A (ko) * 2005-08-24 2007-07-04 에스에스 세야쿠 가부시키 가이샤 수면 개선 의약 조성물
KR20080100284A (ko) * 2006-03-06 2008-11-14 화이자 프로덕츠 인코포레이티드 비-회복성 수면을 위한 알파-2-델타 리간드
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
EP2250143B1 (en) 2008-01-25 2016-04-20 XenoPort, Inc. Method for the enzymatic kinetic resolution of acyloxyalkyl thiocarbonates used for the synthesis of acyloxyalkyl carbamates
US7872046B2 (en) 2008-01-25 2011-01-18 Xenoport, Inc. Crystalline form of a (3S)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use
ES2589915T3 (es) 2008-10-08 2016-11-17 Xgene Pharmaceutical Inc Conjugados de GABA y métodos de utilización de los mismos
EP2509596B1 (en) 2009-12-08 2019-08-28 Case Western Reserve University Gamma aminoacids for treating ocular disorders
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
WO2014117176A1 (en) 2013-01-28 2014-07-31 Lopez Hector L Methods of improving tolerability, pharmacodynamics, and efficacy of b-alanine and use therefor
US20190201395A1 (en) * 2016-05-26 2019-07-04 Amino Up Chemical Co., Ltd. Sleep improving agent
CA3099775A1 (en) 2018-05-14 2019-11-21 Xgene Pharmaceutical Inc. Process for making 1-(acyloxy)-alkyl-carabmate drug conjugates of naproxen and pregabalin
CN117776950B (zh) * 2022-09-20 2025-12-23 中科中山药物创新研究院 一种γ-氨基丁酸衍生物、药物组合物和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
SK282848B6 (sk) * 1996-03-14 2002-12-03 Warner-Lambert Company Premostené cyklické aminokyseliny, farmaceutická kompozícia obsahujúca tieto aminokyseliny
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
KR100589066B1 (ko) * 1997-10-27 2006-06-13 워너-램버트 캄파니 엘엘씨 약제로서 유용한 시클릭 아미노산 및 그의 유도체
US6306910B1 (en) * 1998-07-09 2001-10-23 Warner-Lambert Company Use of Gaba-analogues for treating insomnia
ES2185591T3 (es) * 1999-06-02 2003-05-01 Warner Lambert Co Amino hererociclos utiles como agentes farmaceuticos.
HN2000000224A (es) * 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
AU1808401A (en) * 1999-12-08 2001-06-18 Warner-Lambert Company Method for the stereoselective synthesis of cyclic amino acids
GB9930083D0 (en) * 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
References cited in WO 02/00209 *

Also Published As

Publication number Publication date
WO2002000209A3 (en) 2003-01-16
JP3909842B2 (ja) 2007-04-25
EP1296671A2 (en) 2003-04-02
KR100785182B1 (ko) 2007-12-11
DK1296671T3 (da) 2008-06-16
PT1296671E (pt) 2008-05-09
IL152770A (en) 2009-12-24
MXPA02010668A (es) 2003-03-10
SK17922002A3 (sk) 2003-11-04
HUP0300833A3 (en) 2009-08-28
JP2004501189A (ja) 2004-01-15
PL359872A1 (en) 2004-09-06
TWI298020B (en) 2008-06-21
NZ522480A (en) 2005-06-24
US7141606B2 (en) 2006-11-28
HUP0300833A2 (hu) 2003-08-28
HK1056681A1 (en) 2004-02-27
DE60133389D1 (de) 2008-05-08
DE60133389T2 (de) 2008-06-26
ATE390133T1 (de) 2008-04-15
KR20030019455A (ko) 2003-03-06
AU6473601A (en) 2002-01-08
ZA200209418B (en) 2005-03-10
CZ20024110A3 (cs) 2003-10-15
CA2414008C (en) 2011-04-26
EP1296671B1 (en) 2008-03-26
CN1436075A (zh) 2003-08-13
IL152770A0 (en) 2003-06-24
US20030212133A1 (en) 2003-11-13
CA2414008A1 (en) 2002-01-03
CN1279900C (zh) 2006-10-18
ES2300332T3 (es) 2008-06-16
WO2002000209A2 (en) 2002-01-03
BR0111913A (pt) 2004-01-06

Similar Documents

Publication Publication Date Title
CA2414008C (en) Gabapentin analogues for sleep disorders
AU2001264736A1 (en) Gabapentin analogues for sleep disorders
US4877620A (en) Ibuprofen-containing medicament
ES2244103T3 (es) Remedio para enfermedades neurodegenerativas.
EP0306060B1 (en) Pharmaceutical products providing enhanced analgesia
CA2151724C (en) Antipyretic and analgesic methods and compositions containing optically pure r-ketorolac
RU2005104418A (ru) Фармацевтические композиции для лечения неврологических расстройств, содержащие декстрометорфан и квинидин
HU225534B1 (en) Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors
JP3192141B2 (ja) 抗うつ剤
AU765038B2 (en) Method for the treatment of insomnia
AU2002340971B2 (en) Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
US5519057A (en) Ibuprofen-containing medicament
US20060052455A1 (en) Composition for preventing treating the xepression of clinical symptom in disease caused by mitochondrial dysfunction
ES2237625T3 (es) Uso de un derivado de hidantoina en una composicion farmaceutica contra la hipoalbuminemia.
US5948806A (en) Treatment of Parkinson's disease with (+)2-(ethyl-2,3-dihydrobenzofuranyl)-2-Imidazoline (dexefaroxan or (+) efaroxan)
US3932652A (en) Antidepressant compositions
EP0256629A2 (en) Tolrestat or a salt thereof as an immuno-stimulating agent
US4663345A (en) Etodolac for treatment of gout
US4716177A (en) Tolrestat for inhibition of weight gain
EP1124547A1 (en) Pharmaceutical combination of mildronate and enalapril
RU2174836C1 (ru) Фармацевтическая композиция, обладающая анальгезирующим действием
US3772440A (en) Method for the treatment of parkinsonism and depression
AU2007222112A1 (en) Alpha-2-delta ligands for non-restorative sleep
JP2003277258A (ja) 片頭痛治療剤
MXPA00011647A (en) The treatment of renal colic with gaba analogs

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired